CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
Authors:
- Natalie GrossNGNatalie Gross
- Alexander JochimsenAJAlexander Jochimsen
- Sören DrägerSDSören Dräger
- Thomas TheocharisTTThomas Theocharis
- Andreas ReckeARAndreas Recke
- Nina van BeekNBNina van Beek
- Leon Schmidt-JiménezLSLeon Schmidt-Jiménez
- Steffen KrohnSKSteffen Krohn
- Katja KlauszKKKatja Klausz
- Katja BieberKBKatja Bieber
- Ralf J. LudwigRLRalf J. Ludwig
- Matthias PeippMPMatthias Peipp
Preprint
Abstract
Pemphigoid diseases (PDs) are autoimmune disorders marked by autoantibodies (Aab) against skin and mucous membrane proteins, causing muco-cutaneous blistering in predominantly elderly patients. Since current therapeutics are often insufficient, PDs impose a significant morbidity and mortality burden. CD19×CD3 bispecific T cell engagers (TCEs) - originally developed for B cell malignancies - have shown promise in treatment-refractory autoimmune diseases like systemic sclerosis and rheumatoid arthritis. To explore their potential in PDs, we tested a murine CD19×CD3 TCE in a mouse model of epidermolysis bullosa acquisita (EBA), a prototypical PD. The TCE selectively depleted B cells in blood and bone marrow, but not spleen, of healthy mice. Mice with clinically manifest immunization-induced EBA were randomized to receive either the CD19×CD3 TCE or control treatment upon reaching a predefined disease severity. After 13 weeks, 45% of TCE-treated mice achieved remission, versus 23% of controls. This improvement correlated with reduced antigen-specific B cells, though total and antigen-specific IgG levels were unchanged. These findings suggest that CD19×CD3 TCE preferentially target autoreactive B cells and may be effective at lower doses than those used in oncology. Our data support the potential of CD19×CD3 bispecific T cell engagers as a therapeutic strategy for PDs. eTOC Synopsis: Gross, Jochimsen, Dräger and colleagues demonstrate that CD19×CD3 bispecific T cell engagers, can selectively target autoreactive B cells and induce remission in a mouse model of pemphigoid disease, highlighting their potential as a novel therapeutic strategy for autoimmune blistering disorders.Keywords
Funding Information
- Cluster of Excellence “Precision Medicine in Chronic Inflammation” (EXC 2167), Kiel, DE
- Research Training Group “Defining and Targeting Autoimmune Pre-Disease” (GRK 2633), Luebeck, DE
- Collaborative research center “Pathomechanisms of Antibody-mediated Autoimmunity” (CRC 1526), Luebeck, DE
This publication has 45 references indexed in Scilit:
- Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case studyEuropean Journal of Cancer, 2024
- LB952 A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris (mPV) patients: Preliminary dataJournal of Investigative Dermatology, 2022
- Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa AcquisitaJournal of Investigative Dermatology, 2022
- Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patientsJournal of the American Academy of Dermatology, 2019
- B-Cell Development and Differentiation2019
- Plasma cell survival in the absence of B cell memoryNature Communications, 2017
- Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in GermanyJournal of Investigative Dermatology, 2016
- Dimethylfumarate Impairs Neutrophil FunctionsJournal of Investigative Dermatology, 2016
- Incidence and Mortality of Bullous Pemphigoid in FranceJournal of Investigative Dermatology, 2012
- CD19: a promising B cell target for rheumatoid arthritisNature Reviews Rheumatology, 2009